10-K/A: Health Catalyst Files 10-K/A for 2025 Governance Update

Health Catalyst, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, corporate governance, and director information.

Summary

• This filing is an amendment (Form 10-K/A) to the previously filed 2025 Annual Report.
• The primary purpose is to provide missing information required by Part III of Form 10-K, including details on directors, executive compensation, and related party transactions.
• The filing includes updated biographical information for the board and executive team, reflecting recent leadership changes.
• No changes were made to the previously reported financial statements.
• New certifications from the CEO and CFO are included as required by the Sarbanes-Oxley Act.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative filing, as it highlights significant financial losses, large impairment charges, and executive turnover, despite the improvement in Adjusted EBITDA.

Positives

• Adjusted EBITDA improved to $41.4 million in 2025 compared to $26.1 million in 2024.
• Adjusted EBITDA Margin increased to 13% in 2025 from 9% in 2024.
• The company maintains a pay-for-performance philosophy, with a significant portion of executive compensation tied to equity and performance metrics.
• The company successfully completed the acquisition of Upfront Healthcare Services in 2025.

Negatives

• Net loss increased to $177.97 million in 2025 from $69.50 million in 2024.
• The company recognized $110.2 million in impairment charges for goodwill and intangible assets in 2025.
• Several performance metrics for the 2025 Bonus Plan, including net new platform clients and dollar-based net retention, fell below minimum thresholds.
• The company experienced significant executive turnover, including the retirement of the CEO and the departure of the Chief Operating Officer and Chief Commercial Officer.

Risks

• The company faces risks related to the impairment of goodwill and intangible assets, which could recur if reporting units underperform.
• The company is subject to risks associated with executive leadership transitions and the need to successfully integrate new management.
• The company's ability to achieve growth targets, such as net new platform clients and dollar-based net retention, is critical to future performance.
• The company's reliance on a limited number of large clients or related party contracts, such as Carle Health, presents concentration risk.

Future Outlook

The company continues to focus on its 'Health Catalyst Flywheel' strategy, emphasizing client satisfaction, measurable improvements, and long-term growth. The 2026 compensation program maintains a focus on performance-based incentives and long-term equity alignment.

Management Comments

• Management emphasizes that team member engagement is central to the success of clients and stockholders.
• The company aims to transition executive compensation to levels consistent with its peer group to correlate with sustainable long-term value creation.

Industry Context

StockSavvy.ai notes that Health Catalyst is navigating a challenging environment for healthcare technology firms, characterized by pressure to demonstrate measurable ROI to health system clients and a shift toward profitability over pure top-line growth.

Comparison to Industry Standards

• The company's focus on Adjusted EBITDA improvement aligns with broader industry trends among SaaS and healthcare technology companies prioritizing profitability.
• The use of TSR, Revenue Growth, and Adjusted EBITDA Margin as performance metrics for PRSUs is consistent with standard executive compensation practices for publicly traded technology companies.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company maintains ongoing technology and professional service relationships with Carle Health, where board member Matthew Kolb serves as Executive Vice President and COO, resulting in $17.7 million in revenue in 2025.
• Employment of family members of former executives (Jeffrey Selander and Andrew Cardon).

Stakeholder Impact

• Shareholders may be concerned by the significant net loss and impairment charges.
• Employees may be affected by the leadership changes and the pause in 401(k) matching contributions during the second half of 2025.

Next Steps

• Hold 2026 Annual Meeting of Stockholders.
• Conduct non-binding Say-on-Pay advisory vote.
• Continue execution of 2026 Bonus Plan and RSU equity grants.

Key Dates

Recommendation

The company is in a period of significant transition with new leadership and a need to stabilize financial performance after large impairment charges. Investors should wait for evidence of successful execution under the new CEO before increasing positions.

Keywords

Health Catalyst, HCAT, Healthcare Analytics, Executive Compensation, Corporate Governance, 10-K/A, Adjusted EBITDA